Omburtamab
Based on 1 Customer Validation
Omburtamab is a humanized monoclonal antibody targeting B7-H3 (CD276). Omburtamab selectively binds to B7-H3 highly expressed on the surface of tumor cells and activates anti-tumor immune responses mediated by T cells and natural killer (NK) cells. Omburtamab can promote the specific infiltration of CAR-T cells into tumors, enhance the killing function of NK cells through the CD16 signaling pathway, and regulate tumor cell glucose metabolism (such as inhibiting the Warburg effect). Omburtamab has the potential to inhibit solid tumors such as non-small cell lung cancer (NSCLC).
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.16%
- CAS No.: 1895083-75-6
- 분자량:144.98 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG1 kappa
Human
B7-H3/CD276
Omburtamab (anti-B7-H3 mAb, 8H9) (100 nM; 24 h) significantly inhibits the viability of B7-H3-positive tumor cells (such as A549 and HCT116) and induces cell apoptosis in vitro, and can enhance natural killer cell-mediated tumor cell lysis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A549, HCT 116, OVCAR-3, SK-OV-3, DLD-1, BT-474
-
Concentration:100 nM
-
Incubation Time:24 h
-
Result:Significantly reduced cell viability in B7-H3-positive tumor cell lines, with a dose-dependent decrease in metabolic activity compared to control groups.
-
Cell Line:A549, HCT 116, OVCAR-3, SK-OV-3, DLD-1, BT-474
-
Concentration:100 nM
-
Incubation Time:24 h
-
Result:Resulted a notable increase in apoptosis (Annexin V+/7-AAD+ cells) in A549 and HCT 116 cells, indicating caspase-dependent cell death induction.
-
Cell Line:A549, HCT 116, OVCAR-3, SK-OV-3, DLD-1, BT-474
-
Concentration:100 nM
-
Incubation Time:24 h
-
Result:Co-culture with peripheral blood mononuclear cells (PBMCs) revealed enhanced cytotoxicity against target cells, with specific lysis ratios increasing by 30–50% compared to untreated controls, mediated by CD16 signaling activation.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-kappa
ELISA, FACS, Functional assay
-
Immobilized CD276/B7-H3 Protein, Human (433a.a, HEK293, His, HY-P70652) can bind Omburtamab. The EC50 for this effect is 45.43 ng/mL. -
Flow cytometric analysis of 1.5×106 THP-1 cells with Omburtamab (HY-P99157, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 1895083-75-6
-
Appearance Liquid
-
분자량 144.98 kDa
-
Color Colorless to light yellow
-
SMILES
[Omburtamab]
-
Synonyms
Mab 8H9
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Liu J, et al. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. J Hematol Oncol. 2021 Jan 29;14(1):21. [Content Brief]
[2]. Kaplon H, et al. Antibodies to watch in 2020. MAbs. 2020 Jan-Dec;12(1):1703531. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)